Email updates

Keep up to date with the latest news and content from Critical Care and BioMed Central.

This article is part of the supplement: Sepsis 2012

Open Badges Poster presentation

Clinical utility of using C-reactive protein and procalcitonin as biomarkers for a novel neonatal sepsis diagnostic platform (ASCMicroPlat)

K McAllister1*, M Sheridan-Pereira2, N O'Sullivan2, R O'Kelly2, D Mark3, G Czilwik3, C Martin1, O Sheils1 and J O'Leary1

  • * Corresponding author: K McAllister

Author Affiliations

1 Trinity College Dublin, Ireland

2 The Coombe Women and Infants University Hospital, Dublin, Ireland

3 HSG-IMIT, Lab-on-a-Chip, Freiburg, Germany

For all author emails, please log on.

Critical Care 2012, 16(Suppl 3):P106  doi:10.1186/cc11793

The electronic version of this article is the complete one and can be found online at:

Published:14 November 2012

© 2012 McAllister et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Neonatal sepsis contributes significantly to morbidity and mortality and encompasses a multisystemic inflammatory response to a microorganism. A lack of suitable diagnostic biomarkers and delays in microbe identification (48 to 72 hours) challenge clinical decision-making. C-reactive protein (CRP) is the current biomarker for sepsis in patients; however, use of earlier markers such as procalcitonin (PCT) could prove more effective. This study aims to assess the clinical utility of combining CRP and PCT for a novel sepsis diagnostic biomarker platform (ASCMicroPlat).


Blood samples were obtained from 350 infants evaluated for sepsis at the Coombe Women and Infants University Hospital. Eligible infants met one or more inclusion criteria: age ≤6 weeks, clinical sepsis signs, and/or maternal sepsis risk factors. The puncture site was sterilized with alcohol prior to phlebotomy for microbial and biomarker tests. Blood was collected in clotting activator tubes, and incubated at room temperature for 1 hour before centrifuging to separate out serum for later acute-phase protein quantification. For gold-standard tests, an immunoturbimetric CRP assay was performed using a Beckman analyser and a chemiluminescent Elecsys BRAHMS PCT immunoassay using a Cobas e602 analyser.


The mean age of infant evaluation was 2.29 ± 10.37 days. The average gestational age at birth was 37.04 weeks (4.27), 30% of which were preterm. Eighteen out of 350 samples (5%) were blood culture positive. Thirteen samples met the criteria for a laboratory-confirmed bloodstream infection (LCBSI), the most common organisms being Escherichia coli (28%) and Streptococcus agalactiae (22%). CRP results (n = 350) ranged from ≤0.1 to 226 mg/l, sepsis-positive (≥5 mg/l) CRP tests occurred in 69% of LCBSI. PCT quantified samples to date (n = 100) ranged from 0.03 to 67.23 ng/ml. Both analytes featured in higher cases that suggested sepsis than positive blood culture numbers: 56 out of 350 cases had CRP levels ≥5 mg/l, for PCT 23 out of 100 individuals tested positive at the cutoff (>0.5 ng/ml) for bacterial infection.


Sepsis diagnosis requires accurate detection biomarkers; preliminary study findings show that CRP is present in the majority of bloodstream infections. Furthermore, results using both biomarkers suggest that blood culture results do not indicate all cases of true sepsis. Further research will correlate the completed CRP and PCT gold-standard dataset with that produced by ASCMicroPlat PCR-based assays to assess the clinical utility of this device for sepsis diagnostics.